SGP SpyGlass Pharma, Inc.
Price Chart
Executive Summary
SpyGlass Pharma (SGP) received a cluster of five analyst initiations over the past week, with HC Wainwright & Co. the latest to start coverage at Buy and a $37 price target. The stock currently trades at $24.27, implying 52% upside to the HC Wainwright target. Consensus is overwhelmingly bullish: 8 of 9 analysts rate the stock Buy or Strong Buy, with only one Hold and no Sell ratings. The mean price target of $45 suggests 85% upside from current levels, while the high target of $62 points to 156% upside. HC Wainwright has a 43% accuracy rate on 4,605 calls with an average return of 2.5%, placing it below the typical firm covering SGP. EPS estimates have been revised lower over the past 30 days — the current-year estimate fell from -$1.48 to -$1.64 — but the initiation cluster signals strong institutional conviction in the company's pipeline. No insider trades, congressional activity, or short interest data are available to cross-reference. The bottom line: a high-conviction initiation cluster from five firms, but HC Wainwright's middling track record tempers the signal.
Impact Score
Consensus & Targets
Consensus is heavily bullish: 5 Strong Buy, 3 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 9 analysts. This is a near-unanimous bullish consensus, with only one hold rating preventing a perfect score.
Current price: $24.27. Mean target: $45 (85% upside). Median target: $42 (73% upside). High target: $62 (156% upside). Low target: $37 (52% upside). HC Wainwright's $37 PT is the lowest in the range, sitting 18% below the mean — a relatively conservative stance within a bullish group.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-03-10 | HC Wainwright & Co. | initiate | Buy | — |
| 2026-03-03 | Citigroup | initiate | Buy | — |
| 2026-03-03 | Leerink Partners | initiate | Outperform | — |
| 2026-03-03 | Jefferies | initiate | Buy | — |
| 2026-03-03 | Stifel | initiate | Buy | — |
30-day analyst activity: 0 upgrades, 0 downgrades — all five actions are initiations. EPS revisions are trending negative: the current-year estimate fell from -$1.48 to -$1.64 over the past 30 days, and the next-quarter estimate dropped from -$0.33 to -$0.39. Revisions are being revised lower, which is a cautionary signal against the bullish initiations.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $-0.36 | $-0.49 — $-0.23 | $0.00 | ↑0 ↓0 |
| +1y | $-1.92 | $-2.40 — $-1.46 | $0.00 | ↑1 ↓0 |
| 0y | $-1.64 | $-2.02 — $-1.19 | $0.00 | ↑1 ↓0 |
| +1q | $-0.39 | $-0.50 — $-0.28 | $0.00 | ↑0 ↓0 |
Actionable Insight
The five-firm initiation cluster is a strong bullish signal, but HC Wainwright's below-average accuracy and the negative EPS revision trend warrant caution. Traders should view this as a positive catalyst but wait for confirmation from price action above $26 before adding size.
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 24, 2026
19d ago
|
ANALYST-UPGRADE
| $26.82 $27.20 | ▲ +1.42% | ▲ +2.32% | $18.44 (−31.25%) |
|
May 14, 2026
29d ago
|
8-K
| $23.21 $20.84 | ▼ −10.21% | ▼ −11.17% | $18.44 (−20.55%) |
|
Apr 16, 2026
8w ago
|
ANALYST-UPGRADE
| $24.94 $23.52 | ▼ −5.69% | ▼ −6.25% | $18.44 (−26.06%) |
|
Mar 26, 2026
11w ago
|
Press Release
| $22.61 $22.65 | ▲ +0.18% | ▼ −3.69% | $18.44 (−18.44%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $27.12 $27.10 | ▼ −0.07% | ▲ +1.28% | $18.44 (−32.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access